On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.

Conducting the study in New Mexico allowed for the collection of data on the effectiveness and safety of bamlanivimab in a real-world setting that included a diverse population and spans both rural and urban environments.